UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application **Commissioner for Patents** P. O. Box 1450 Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

DOX 1450, Michandra,	
13 April	2004
Date of Deposy	
Signature	
EL 9648	41657 US
Express Mail No.	

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: FRAV2003/0009 US NP

INVENTORS: GUILLAUME, et al.

METHOD FOR OBTAINING TITLE:

MASTOCYTE LINES FROM PIG TISSUES AND FOR

PRODUCING HEPARIN-TYPE MOLECULES

APPLICATION ELEMENTS

1.	\boxtimes	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)		
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	37
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets	10
4.	Oath a.	or Declaration Newly unexecuted (original or copy)	Total Pages	2
	b.	Copy from a prior application (37 CFR § 1	.63(d))	
		i. DELETION OF INVENTOR(S) Signed statement attached deleting application, see 37 CFR §§ 1.63(d)(3)	inventor(s) nan 2) and 1.33(b).	ned in the prior
5.	Pow a.	er of Attorney Newly executed (original or copy)	Total Pages	
	b.	Copy from a prior application (37 CFR § 1	.63(d))	
6.		Microfiche Computer Program (Appendix)		

Applio	lication Transmittal Letter 2				
7.	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Copy b. Paper Copy (identical to computer copy) c. Statement verifying identity of above copies				
	If a CONTINUING Application, check appropriate box, and supply the requisite information: Continuation Divisional Continuation-in-part of prior application no: , filed , Examiner , Group/Art Unit (The cross reference has been/will be inserted on page one of the specification).				
\boxtimes	This application claims the benefit of U.S. Provisional Application No. 60/477,962, filed June 12, 2003. (The cross reference has been/will be inserted on page one of the specification).				
Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.					
ACC	OMPANYING APPLICATION PARTS				
7.	Assignment Papers (cover sheet & document(s))				
8.	37 CFR §3.73(b) Statement (when there is an assignee)				
9.	Verified English Translation Document (if applicable)				
10.	Consider of IDS Citations				
11.	11. Preliminary Amendment				
12.	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)				
13.	*Small Entity Statement(s) (PTO/SB/09-12) Statement filed in prior application, Status still proper and desired				
14.	Certified Copy of Priority Document(s) (if foreign priority is claimed)				
15.					
COI	RRESPONDENCE ADDRESS				
Customer Number or Bar Code Label 005487					
	(Insert Customer No. or Attach bar code label here)				
	0				
	Joel B. German, Reg. No. 48,676 Attorney/Agent for Applicant				
Ave	ntis Pharmaceuticals Inc.				
Pate	ent Department te #202-206 / P.O. Box 6800				

Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3444
Telefax (908) 231-2626
Aventis Docket No. FRAV2003/0009 US NP

Approved for use through 04/30/2003. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Patent fees are subject to annual revision. Applicant claims small entity status. See 37 CFR 1.27

OTAL AMOUNT C	F PAYMENT	(\$) 2620.0

Complete if Known				
Application Number	Not Yet Assisgned			
Filing Date	April 13, 2004			
First Named Inventor	GUILLAUME, et al.			
Examiner Name	Not Yet Known			
Group / Art Unit	Not Yet Known			
Attorney Docket No.	FRAV2003/0009 US NP			

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)					
Check Credit Card Money Other None Order		3. ADDITIONAL FEES				
Deposit Account	Large E		Small En	Fee		
Deposit Account Number	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
Deposit Account Aventis Pharmaceuticals Inc.		130	2051	65	Surcharge - late filing fee or oath	
Name The Commissioner is authorized to: (check all that apply)	1051			•	Surcharge - late provisional filing fee or	
Charge fee(s) indicated below Credit any overpayments	1052	50	2052	25 130	cover sheet Non-English Specification	
Charge any additional fee(s) during the pendency of this application	1053 1812	130 2,520	1053 1812	130 2,520	For filing a request for reexamination	
Charge fee(s) indicated below, except for the filing fee		920*	1804	920*	Requesting publication of SIR prior to	
to the above-identified deposit account	4	4 4	400-	4.040-	Examiner action	
FEE CALCULATION	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1. BASIC FILING FEE	1251	110	2251	55	Extension for reply within first month	
Large Entity Small Entity Fee Fee	1252	420	2252	205	Extension for reply within second month	
Code (\$) Code (\$) 1001 770 2001 375 Utility filing fee 770	1253	950	2253	465	Extension for reply within third month	
1002 340 2002 165 Design filing Fee	1254	1,480	2254	725	Extension for reply within fourth month	
1003 530 2003 260 Plant filing fee	1255	2,010	2255	985	Extension for reply within fifth month	
1004 770 2004 375 Reissue filing fee	1401	330	2401	160	Notice of Appeal	
1005 160 2005 80 Provisional filing fee	1402	330	2402	160	Filing a brief in support of an appeal	<u> </u>
SUBTOTAL (1) (\$)770.00	1403	290	2403	140	Request for oral hearing	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE		1,510	1451	1,510	Petition to institute a public use proceeding	
Fee		110	2452	55	Petition to revive - unavoidable	1
Extra from Fee Claims below Paid			Ī			
Total Claims 75 -20**= 55 x 18 = 990	1453	1,330	2453	650	Petition to revive - unintentional	
Independent 13 - 3**= 10 x 86 = 860	1501	1,330	2501	650	Utility issue fee (or reissue)	
Claims	1502	480	2502	235	Design issue fee	
Multiple Dependent x =	1503	640	2503	315	Plant issue fee	
minuple Dependent ^	1460	130	1460	130	Petitions to the Commissioner	
Large Entity Small Entity	1807	50	1807	50	Petitions related to provisional applications	
Fee Fee Fee Fee			1			
Code (\$) Code (\$) Fee Description	1806	180	1806	180	Submission of Information Disclosure Stmt	
1201 86 2201 42 Independent claims in excess of 3	1	40	8021	40	Recording each patent assignment per property (times number of properties)	
1203 290 2203 140 Multiple dependent claim, if not paid	1809	770	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1204 86 2204 42 **Reissue independent claims over original patent	1810	770	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1205 18 2205 9 **Reissue claims in excess of	1801	770	2801	375	Request for Continued Examination (RCE)	L
20 and over original patent	1802	900	1802	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$) 1850.00	Other fe	ee (specify	n)			
**or number previously paid, if greater; For Reissues, see above	*Reduc	ed by Bas	sic Filing Fe	e Paid	SUBTOTAL (3) (\$)	

Complete (If applicable) SUBMITTED BY Registration No. (908) 231-3444 48,676 Telephone Joel B-German, Reg. No. 48,676 Name (Print/Type) (Attomey/Agent) 4/13/2004 Date Signature

WARNING: Information on this form may become public. Credit card information should not be

Included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.